Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
about
Eltrombopag in patients with chronic liver disease.Platelet count and sustained virological response in hepatitis C treatment.Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries.Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.Thrombocytopenia in chronic liver disease.Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study.Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosisBone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.Thrombocytopenia in patients with chronic liver disease: what's in a name?
P2860
Q33406181-4EAF4819-64C8-4349-9B0E-5CE50DD6EA54Q33407719-00750A5A-EBB5-4619-A83F-CFC5966E9ABEQ33410537-63418D58-A7AD-46A7-8101-06F07CD7C7DBQ33414392-AB61965F-3BF0-4C38-8D78-1217CB0AB277Q33421239-ED4BE254-144B-4947-BEED-0BEEDC3F3611Q33423922-6FFF09E8-3B6C-4E2A-8EFE-3A260C566ADCQ33424436-C8653253-E29A-49DF-A274-F59ABAF30780Q33427048-0D416C9A-1484-401D-AC60-1A9CC373EDC1Q33436905-D86D4B5A-2FD6-42DE-917A-7E3A16D2AD67Q34467312-2C634EDE-C579-4955-B1D7-9706A949BEEEQ35930606-8D58AA11-E118-4B51-BDD6-94A132CF9956Q40333567-35C210D5-212A-43F2-A074-17350DDB545AQ44690091-6163F53A-B8EC-4A78-B304-CBB0085168D3Q48592088-D73EAACA-B2DD-4F98-95A4-E2CF6D939E4D
P2860
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@ast
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@en
type
label
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@ast
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@en
prefLabel
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@ast
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@en
P2093
P2860
P1433
P1476
Peripheral blood cytopaenia li ...... ligible for antiviral therapy.
@en
P2093
Antonino Picciotto
Giulia Pieri
Simona Marenco
Valentina Fazio
Vincenzo Savarino
P2860
P304
P356
10.1111/J.1478-3231.2012.02798.X
P577
2012-04-04T00:00:00Z